Valeo Pharma Obtains Public Reimbursement For Asthma Drugs In Alberta, One Step Closer to 2025 Revenue Target of $160 Million

Valeo Pharma is already a successful, revenue-generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market. This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. Q3 Highlights: Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter. Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter. Record 9 months revenues at $10.2 million , up 94% In this week’s announcement, Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta. Highlighted by the following: First provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage is expected to follow soon 85% private payer health plan coverage across Canada As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025. Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.